Five-point-five percent 5.5% of these patients displayed somatic alterations classified as 2b, defined as an approved biomarker in another cancer indication and included ERBB2 amplifications, CDK4 amplifications, BRCA1/2 mutations, BRAFV600E mutation and fusion events involving ROS1 and ALK1 [219]. This evidence concerns the gene CDK4 and cancer.